MENUNew $2.3 million workplace intervention aims to reduce exposure risk for oncology nurses
Media Contacts: Mary Beth Lewis, University of Michigan School of Nursing, [email protected], 734-763-1682 and Nicole Fawcett, U-M Rogel Cancer Center, [email protected], 734-764-2220
Study is designed to promote safety at chemotherapy infusion sites
ANN ARBOR, Mich. -- Researchers at the University of Michigan School of Nursing and Rogel Cancer Center have received a $2.3 million grant to study oncology nurses’ exposure to hazardous drugs, including identifying ways to reduce exposure.
“There are significant acute and long-term side effects from hazardous drug exposures in oncology settings, but not enough evidence-based, risk-reduction efforts to protect health care workers,” says Christopher Friese, Ph.D., R.N., AOCN®, FAAN, University of Michigan School of Nursing assistant professor and member of U-M’s Rogel Cancer Center and Institute for Healthcare Policy and Innovation.
Friese aims to lower the risk through a new study called DEFENS: Drug Exposure Feedback and Education for Nurses’ Safety. The four-year study, with funding from the National Institute for Occupational Safety and Health (NIOSH), will examine oncology nurses’ use of personal protective equipment (PPE) and biological exposure to hazardous drugs at approximately a dozen health care institutions nationwide.
“Nurses are the single largest group of oncology care providers,” Friese says. “Patients and families work with nurses the most when chemotherapy is part of treatment. It's important to recognize the need for well-prepared oncology nurses to deliver care safely and avoid poor outcomes.”
Worker exposure to hazardous drugs like chemotherapy is a “persistent problem” and may result in adverse health effects. In a preliminary study, Friese found that among 242 surveyed oncology nurses, 16.9 percent reported skin or eye exposure to hazardous drugs in the past year. Organizational factors such as nursing workloads, practice environments, and performance of safety behavior are associated with an increased risk of spills.
The four-year study has two key components. First, nurses will provide information concerning chemotherapy spills in the clinic and provide blood samples to determine whether the agents are detectable. Second, nurses will receive an educational module on safe drug handling, with and without specific feedback about how to improve their practice. The goal is to increase the number of nurses who use protective equipment likes gowns and gloves on a consistent basis. Eleven of the nation’s leading cancer centers and more than 300 nurses will participate.
This multidisciplinary study will also include co-investigator Duxin Sun, Ph.D., professor at the U-M College of Pharmacy and director of University of Michigan Pharmacokinetics Core. He will oversee the development, testing and interpretation of the results obtained from participants’ plasma to detect hazardous drug levels. Co-Investigator Marjorie McCullagh, Ph.D., R.N., APHN-BC, COHN-S, associate professor of nursing, director of the Occupational Health Training Program and contributing faculty to U-M’s NIOSH-funded Education and Research Center, will contribute to the protocol development surrounding participant recruitment and retention, assist in the interpretation of study results and development of future interventions.
“Over 20 million doses of chemo are given annually in infusion centers. We believe the data gathered from this study can be used to inform practice and make policy changes that will improve the safety of a large number of health care workers,” Friese says.
For questions please email [email protected] , on twitter @DEFENSStudy or contact Kari Mendelsohn-Victor, MPH, at 734-615-4017.
Research reported in this release is supported by the National Institute for Occupational Safety and Health under grant number: R01OH010582. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIOSH.